Latanoprost + Timolol Comp. Abz

Latanoprost and timolol maleate, the active ingredients in Latanoprost + Timolol Comp. Abz, are a prostaglandin analog and a non‑selective beta‑blocker presented as an ophthalmic solution for ocular use. They are indicated for lowering intra‑ocular pressure in glaucoma and ocular hypertension. GNH USA supplies Latanoprost + Timolol Comp. Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol acts on the ocular pressure regulation pathway to manage glaucoma‑related conditions. Primary open‑angle glaucoma: reduces intra‑ocular pressure to protect the optic nerve. Ocular hypertension: lowers elevated eye pressure to within normal limits. Glaucoma suspect: helps maintain target pressure while monitoring disease progression.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision shortly after instillation - Conjunctival hyperemia (redness) - Itching or mild allergic reaction on the eyelid - Dry eye or foreign‑body sensation - Increased pigmentation of the iris Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis) - Marked bradycardia or heart block - Bronchospasm or worsening asthma - Systemic hypotension - Persistent ocular inflammation - Unexpected visual loss

Before initiating therapy, consider the following precautions. Assess cardiovascular status: evaluate for bradycardia, heart block, or heart failure. Screen for respiratory disease: avoid in patients with uncontrolled asthma or severe COPD. Monitor intra‑ocular pressure: ensure target pressure is achieved and maintained. Avoid concurrent systemic beta‑blockers: may increase risk of systemic hypotension. Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines as follows. Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: additive bradycardia or hypotension. - Calcium channel blockers: may potentiate ocular hypotensive effect. - Monoamine oxidase inhibitors: risk of severe hypotension. Moderate Interactions (Monitor Closely): - Other prostaglandin analogues: increased ocular irritation. - Topical corticosteroids: may reduce the efficacy of pressure lowering. - Anticholinergic agents: possible alteration of pupil dynamics.